Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 17/20 | 0.42 |
| ▸ | JAK2 | O60674 | 5/20 | 0.42 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 7/20 | 0.40 |
| ▸ | JAK3 | P52333 | 7/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25241529 | 1.00 | JAK1 (0.42) | JAK1JAK2HTR6MAOBTYK2 | |
| SCHEMBL25699287 | 1.00 | JAK1 (0.42) | JAK1JAK2HTR6MAOBTYK2 | |
| SCHEMBL2223896 | 1.00 | JAK1 (0.42) | JAK1JAK2HTR6MAOBTYK2 | |
| SCHEMBL25283735 | 1.00 | JAK1 (0.42) | JAK1JAK2HTR6MAOBTYK2 | |
| SCHEMBL29460490 | 1.00 | JAK1 (0.42) | JAK1JAK2HTR6MAOBTYK2 | |
| SCHEMBL2280654 | 0.95 | JAK1 (0.45) | JAK1JAK2HTR6MAOBTYK2 | |
| SCHEMBL2224738 | 0.95 | JAK1 (0.46) | JAK1JAK2HTR6TYK2JAK3 | |
| SCHEMBL2273561 | 0.89 | JAK1 (0.43) | JAK1JAK2HTR6MAOBTYK2 | |
| SCHEMBL2273559 | 0.89 | JAK1 (0.43) | JAK1JAK2HTR6MAOBTYK2 | |
| SCHEMBL2282946 | 0.88 | JAK1 (0.54) | JAK1JAK2TYK2JAK3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383898-A1 | PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION | YIYOU BIOTECH (SHANGHAI) CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| EP-4393923-A1 | PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION | Yiyou Biotech (Shanghai) Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383898-A1 | PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION | JAK1, WEE1, JAK2 | JAK1 1/4885JAK2 3/4885HTR6 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.